Turkish neurosurgery · 2011
Comparison of two different formulations of botulinum toxin A for the treatment of blepharospasm and hemifacial spasm.
Сравнительное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Chuan-Jie, Shen Ji-Hong, Chen Yuan, Lian Ya-Jun
Аннотация
AIM: To confirm and compare the therapeutic efficacies and adverse effects of Chinese botulinum toxin type A (CBTX-A, Lanzhou Biological Products Institute, China) and current Botox (Allergan Inc., CA, USA) in the treatment of blepharospasm (BS) and hemifacial spasm (HFS).
MATERIAL AND METHODS: We performed an open, prospective, comparative trial comparing CBTX-A and Botox for the treatment of BS and HFS in 273 patients since 2006. 107 patients were treated with current Botox and 166 with CBTX-A, with the age, disease durations and severity of spasm matched. The patients enrolled were followed up for 6 months.
RESULTS: There were no significant differences in the clinical effects of the two preparations, including the onset of response, peaked effect time and duration of effects (p > 0.05). The Cohen scores showed a significant reduction after BTX-A injections. Considerable improvement of symptoms for the BS and HFS patients was observed 7 days, 4 weeks, 12 weeks, and 24 weeks after the injection with either current Botox or CBTX-A (p < 0.05). There was no significant difference in the effectiveness rate for both HFS patients and BS patients between CBTX-A group and Botox group (p > 0.05). No statistical differences were noted in adverse reactions between them (p > 0.05).
CONCLUSION: The two preparations were both simple and effective for the patients with blepharospasm and hemifacial spasm.
MATERIAL AND METHODS: We performed an open, prospective, comparative trial comparing CBTX-A and Botox for the treatment of BS and HFS in 273 patients since 2006. 107 patients were treated with current Botox and 166 with CBTX-A, with the age, disease durations and severity of spasm matched. The patients enrolled were followed up for 6 months.
RESULTS: There were no significant differences in the clinical effects of the two preparations, including the onset of response, peaked effect time and duration of effects (p > 0.05). The Cohen scores showed a significant reduction after BTX-A injections. Considerable improvement of symptoms for the BS and HFS patients was observed 7 days, 4 weeks, 12 weeks, and 24 weeks after the injection with either current Botox or CBTX-A (p < 0.05). There was no significant difference in the effectiveness rate for both HFS patients and BS patients between CBTX-A group and Botox group (p > 0.05). No statistical differences were noted in adverse reactions between them (p > 0.05).
CONCLUSION: The two preparations were both simple and effective for the patients with blepharospasm and hemifacial spasm.
Предметные рубрики MeSH
AdultAgedAged, 80 and overBlepharospasmBotulinum Toxins, Type AChemistry, PharmaceuticalDose-Response Relationship, DrugFacial MusclesFacial NerveFacial Nerve DiseasesFemaleHemifacial SpasmHumansMaleMiddle AgedNeuromuscular AgentsNeuromuscular JunctionProspective StudiesSeverity of Illness IndexTreatment OutcomeYoung Adult